Explanation on why giritinib (segatan) cannot be taken continuously for more than three months

Gilteritinib (Gilteritinib) is an oral FLT3 inhibitor, mainly used to treat FLT3 mutation-positive acute myeloid leukemia (AML) patients. The drug inhibits leukemia cell proliferation and induces apoptosis by inhibiting the activity of FLT3 tyrosine kinase and blocking downstream signaling pathways. In clinical practice, although giritinib has significant efficacy, long-term continuous use requires caution and is usually not recommended for more than three months.

Continuous long-term use of giritinib may lead to the accumulation of adverse reactions such as bone marrow suppression, abnormal liver function, and prolongation of the QT interval. When platelets, white blood cells, and red blood cells decrease significantly, patients are prone to risks such as infection, bleeding, and anemia. In addition, long-term high-dose inhibition of the FLT3 pathway may increase the probability of drug-resistant mutations and affect the efficacy of subsequent treatments.

Based on clinical trials and safety evaluation, gilitinib is usually administered in a short-term continuous dosage regimen combined with periodic hematology monitoring. Three months is the recommended upper limit of continuous use. Beyond this time, adjustments or discontinuation must be made based on the patient's blood picture, liver and kidney function, and treatment response. By taking medications periodically, leukemia can be controlled while reducing the incidence of serious adverse reactions.

While using giritinib, patients should strictly follow the doctor's prescription and follow-up plan, and regularly monitor blood images, liver and kidney function, and electrocardiogram indicators. If bone marrow suppression or cardiac abnormalities occur, the drug should be discontinued or the dose should be adjusted promptly. Establishing a standardized medication management and follow-up mechanism can not only ensure the efficacy of the medication, but also reduce the risks of long-term use and provide patients with safe and effective treatment options.

Reference materials:https://www.drugs.com/